Filing Details

Accession Number:
0001140361-20-027382
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-04 17:13:38
Reporting Period:
2020-12-02
Accepted Time:
2020-12-04 17:13:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1797768 Kinnate Biopharma Inc. KNTE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282930 L Carl Gordon 11975 El Camino Real, Suite 101
San Diego CA 91230
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-02 300,000 $20.00 300,000 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-12-02 450,000 $20.00 450,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The shares are held of record by OrbiMed Private Investments VII, LP (OPI VII). OrbiMed Capital GP VII LLC (OrbiMed GP VII) is the general partner of OPI VII and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of OrbiMed GP VII. By virtue of such relationships, OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of OrbiMed Advisors. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VII.
  2. The shares are held of record by OrbiMed Partners Master Fund Limited (OPM). OrbiMed Capital LLC (OrbiMed Capital) is the investment advisor to OPM. OrbiMed Capital is a relying adviser to OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM.